If you searched for a way to buy Exscientia shares, start with a key update: EXAI is no longer a separately traded Nasdaq security. Recursion Pharmaceuticals completed its acquisition of Exscientia in November 2024, and Exscientia American Depositary Shares ceased trading. This guide explains what changed and how to research the situation without relying on outdated broker lists.
Nasdaq records November 19, 2024 as the last trading date for EXAI. The merger closed on November 20, 2024. A broker page that still presents EXAI as an ordinary, currently purchasable stock may be outdated.
Can you still buy Exscientia (EXAI) shares?
Not as a normal, independently listed Nasdaq stock. Exscientia was acquired by Recursion Pharmaceuticals, and the EXAI American Depositary Shares stopped trading as part of the transaction. If a trading app still displays an old EXAI page, check whether it is historical data, a corporate-action record or an inactive instrument rather than an available security.
Do not send money to a website that promises to sell you “pre-merger EXAI shares” without clear, verifiable custody and legal documentation. A ticker appearing in an old article or quote feed is not proof that the security can currently be purchased.
Primary sources: Nasdaq corporate-action notice and Recursion’s merger announcement.
What happened in the Recursion–Exscientia merger?
The transaction became effective on November 20, 2024. Under the announced terms, each Exscientia ordinary share or ADS was exchanged for 0.7729 shares of Recursion Class A common stock. Exscientia then became a wholly owned subsidiary of Recursion and EXAI ceased trading on Nasdaq.
This corporate-action summary is historical context, not a statement about the current value of RXRX or a recommendation to buy it. Always check the latest filings and market data before making an investment decision.
What if you want exposure to the business today?
Investors researching Exscientia’s former business may want to study Recursion Pharmaceuticals (RXRX), the public company that acquired it. That is a different investment decision: the buyer has its own pipeline, finances, partnerships, share count and risks. Past Exscientia research should not be treated as a current valuation of Recursion.
- Read Recursion’s latest annual and quarterly filings on the SEC EDGAR database.
- Review company announcements, clinical-program updates, cash runway and any new share issuance.
- Understand that drug-development timelines are uncertain and clinical setbacks can cause large price moves.
- Compare the market price with your own assessment of risk; do not rely on old price targets or archived stock articles.
How to buy a publicly traded stock through a broker
The steps below apply to an eligible, currently listed security—not to inactive EXAI shares.
- Check the listing. Confirm the ticker, exchange and active trading status using an exchange or regulatory filing.
- Choose an eligible broker. Confirm the broker accepts residents of your country and provides access to the relevant exchange.
- Review costs. Check commissions, currency conversion, custody or inactivity fees, and any minimums before funding.
- Open and verify the account. Use the broker’s official site, complete identity checks and secure the account with multi-factor authentication.
- Research the company. Read current filings, understand the business and decide how much loss you could tolerate before placing an order.
- Use an appropriate order type. Review the order preview, currency, quantity and total estimated cost before confirming.
Risks to consider before investing in biotech
Biotechnology shares can be unusually volatile because their prospects may depend on clinical-trial results, regulatory decisions, intellectual-property rights, partnerships and the ability to raise additional capital. Even a promising technology platform may not translate into an approved medicine or profitable business.
For any current security, read the latest company filings, understand dilution risk and avoid investing money needed for near-term expenses. Diversification can reduce company-specific concentration, but it cannot eliminate market losses.
Frequently asked questions
Is EXAI still listed on Nasdaq?
No. Nasdaq’s corporate-action notice records November 19, 2024 as the last trading date, followed by suspension/delisting associated with the completed acquisition.
Did Exscientia shareholders receive Recursion shares?
The merger terms provided 0.7729 shares of Recursion Class A common stock for each Exscientia share/ADS, subject to the transaction’s legal terms and processing. Former holders should consult their broker statements and tax adviser for their own records.
Is RXRX the same stock as EXAI?
No. RXRX is Recursion’s ticker. The companies combined, but the securities, capital structure and business outlook are not interchangeable.
Can this guide tell me whether to buy RXRX?
No. It provides historical corporate-action information and a research checklist, not personalized investment advice.
Reviewed October 21, 2026. Verify current listings, filings and broker eligibility before acting.
